Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Biotechs remain voracious consumers of capital, but tapping the equity markets is often prohibitively dilutive. Royalty financing can provide lower-cost-of-capital funding while putting a price on assets the market often ignores. This cash can also allow biotechs to hold onto R&D projects longer, eventually pushing up the price of licensing deals. But although royalty financiers are eager, they are limited in the amount of risk they are willing to take; new players in the business though may nevertheless increase competition and drive prices up.
You may also be interested in...
Freedom And Capital Drive Intarcia Down Independent Path
With a lucrative and unique royalty financing deal and positive first results from its global Phase III diabetes study, Intarcia has emerged as one of the biotech industry’s most valuable private companies and is in position to control its own destiny. It just may disrupt the type 2 diabetes market in the process.
CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics
Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.
OrbiMed Launches $600M Royalty Fund
The diversified investment firm will aim for low-risk investments that bring faster returns to inventors, research institutions and smaller drug developers.